A carregar...
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
BACKGROUND: Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic cancers....
Na minha lista:
| Publicado no: | BMC Nephrol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5767063/ https://ncbi.nlm.nih.gov/pubmed/29329518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-018-0812-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|